Congenital Panhypopituitarism: Overcoming the Odds
Published: 2012-09-16 - Updated: 2021-07-26
Author: Rx&D | Contact: Disabled World (Disabled-World.com)
Synopsis: Diagnosed at age 8 doctors discovered Maureen had congenital panhypopituitarism where her body did not produce growth hormone or stimulation to her endocrine glands. Congenital Panhypopituitarism is a condition of inadequate or absent production of the anterior pituitary hormones. Congenital hypopituitarism is potentially fatal in the newborn period but treatable if the diagnosis is made early. It is frequently the result of other problems that affect the pituitary gland and either reduce or destroy its function or interfere with hypothalamic secretion of the varying pituitary-releasing hormones.
Twenty years ago Maureen Smith's optimism and hopeful outlook was starting to wane. Her body was deteriorating and everyday activities were a struggle. A rare hormonal disorder continued to wreak havoc on her body - as it had since she was born.
Maureen has congenital panhypopituitarism. Diagnosed at age 8, doctors discovered Maureen's body didn't produce growth hormone and there was no stimulation to her endocrine glands. Her growth was stunted and she had the skeletal composition of a four year-old. But as a child Maureen had hope. She was enrolled in a clinical trial for human growth hormone in Montreal that would replace what her body could not produce.
Congenital Panhypopituitarism is a condition of inadequate or absent production of the anterior pituitary hormones. It is frequently the result of other problems that affect the pituitary gland and either reduce or destroy its function or interfere with hypothalamic secretion of the varying pituitary-releasing hormones. Congenital hypopituitarism is potentially fatal in the newborn period but treatable if the diagnosis is made early. While hypopituitarism is common, congenital hypopituitarism is rare. Even rarer is the successful diagnosis and management of this condition in the neonatal period, especially when accompanied by other comorbid conditions.
"I received the drug for six months at a time. For six months I would feel sluggish and ill but then I would get the drug and for the next six months I would feel normal," says Maureen. "The trial worked very well and I grew to just over five feet."
But the trial was for children and at age 18 Maureen withdrew herself to allow another child to take her place. Years later a synthetic version of the growth hormone was developed but it was again only approved for use in children. Over the next 20 years Maureen began to deteriorate. She fractured her back and had to begin using a walker, fat began to encase her heart and she was in and out of the hospital. Maureen was determined not to let her disease dictate her life. She began searching for a way to gain access to the new synthetic hormone, and she needed a doctor who was willing to help.
"When you're very ill all you concentrate on is getting better."
After years of letter writing and fighting for access to the medicine she so desperately needed, at age 38, Maureen was admitted to a new clinical trial providing the synthetic hormone to adults. It was instant relief.
"It changed my life. I threw away my walker, began riding a bike and laced up my skates," says Maureen. It took seven years for her doctor to find the right dose but now Maureen's condition is under control. "I'm healthier now at 53 than I was at 25. I have a quality of life now that I never dreamed of in my 30's."
That new quality of life includes her recent marriage to Jim McQuaid.
"It's difficult to meet people when you have an illness," says Maureen. "When I got better I was able to find a wonderful man and we have a terrific life together. I wouldn't have any of this without my new medication."
There are good days and there are some bad but Jim takes them in stride and is thankful for the new life they have together.
"There are some stresses but for the most part she functions very well. I'm always amazed at how a handful of pills can change a person in a couple of hours," says Jim.
Maureen now focuses her attention on the needs of others, working for the Canadian Organization for Rare Disorders (CORD), a national network for organizations representing all those with rare disorders. CORD is currently advocating for a national orphan drug policy for the treatment of rare disorders.
"I'm very passionate of the work I do with CORD," says Maureen. "Only fifty percent of the medications available for rare diseases are available in Canada. I know first-hand what it's like not to have access to a drug."
"Without her medicine, I presume she would be lying in a bed somewhere and I wouldn't have met her," says Jim.
Maureen also takes the time to share her story with others and using opportunities to meet with researchers to thank them for the daunting work they do.
"I always say thank you and to please continue working. I am the embodiment of what they do and I am standing here today because of their research."
There is a lot of work to be done but Maureen is hopeful for the future. "I always had hope, I didn't give up but it was very difficult. Now all I see is the future and I take care of myself so I can make the most of it."
- Video with caption:
"Maureen Smith has a rare hormonal disorder and is living proof that new medicines matter and can make a world of difference."
Video available at: www.youtube.com/watchv=RMYoSTOphRw&feature=plcp
- Audio with caption:
"Maureen talks about her illness from when she was first diagnosed, through her symptoms as a child, her initial treatment, and the 20 year period from 18 to 38 when she had no available treatment, during which her health deteriorated rapidly. Eventually, at 38 she found a clinical trial for a new medicine that reversed her symptoms. She is now 53, newly married, and lives a healthy happy life in Ottawa with her husband Jim."
Audio available at: stream1.newswire.ca/media/2012/09/16/20120916_C6899_AUDIO_EN_17906.mp3
- Audio with caption:
"Maureen describes the symptoms of her illness as a child and the treatment she received through a clinical trial to stop the progression of her illness. She stopped receiving treatment at 18 to allow other children to benefit from the clinical trial."
Audio available at: stream1.newswire.ca/media/2012/09/16/20120916_C6899_AUDIO_EN_17907.mp3
- Audio with caption:
"Maureen talks about the 20 year period when she didn't have access to the medication she needed. She talks about the decline of her health, and some specifics incidents that describe the nature of her condition. Finally at 38, she was able to participate in a clinical trial for a new medicine that reversed her symptoms and allows her to lead a normal healthy life."
Audio available at: stream1.newswire.ca/media/2012/09/16/20120916_C6899_AUDIO_EN_17908.mp3
- Audio with caption:
"Maureen talks about the overwhelming feeling of gratitude she has for her medicine and her hopes for the future."
Audio available at: stream1.newswire.ca/media/2012/09/16/20120916_C6899_AUDIO_EN_17909.mp3
Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.
Primary Information Source(s):
Congenital Panhypopituitarism: Overcoming the Odds | Rx&D (Disabled World (Disabled-World.com)). Disabled World makes no warranties or representations in connection therewith. Content may have been edited for style, clarity or length.
In Other News:
You're reading Disabled World. See our homepage for informative disability news, reviews, sports, stories and how-tos. You can also connect with us on social media such as Twitter and Facebook or learn more about Disabled World on our about us page.
Disclaimer: Disabled World provides general information only. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World.
Cite This Page (APA): Rx&D. (2012, September 16). Congenital Panhypopituitarism: Overcoming the Odds. Disabled World. Retrieved September 22, 2021 from www.disabled-world.com/medical/pharmaceutical/odds.php